2. Search Result
Search Result
Results for "

E2F-1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Recombinant Proteins

8

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS04110
    E2F1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    E2F1 Human Pre-designed siRNA Set A contains three designed siRNAs for E2F1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    E2F1 Human Pre-designed siRNA Set A
    E2F1 Human Pre-designed siRNA Set A
  • HY-175397
    Dth

    DFHBI-thalidomide

    		 PROTACs NF-κB Early 2 Factor (E2F) Bcl-2 Family VEGFR Cancer
    Dth (DFHBI-thalidomide) is an RNA aptamer-based PROTAC degrader. Dth can degrade a variety of endogenous proteins (such as mCherry, p50, p65 and E2F1) by replacing the 3′ module on the RNA scaffold with the RNA aptamer corresponding to the target protein. Dth upregulates IκB-α and Bax, and downregulates Bcl-2 and VEGF. Dth generates green fluorescence upon binding to the Broccoli RNA aptamer, enabling the tracing of RNA scaffolds. Dth can be used in cancer-related research .
    Dth
  • HY-117857
    MRT00033659

    		Casein Kinase Checkpoint Kinase (Chk) MDM-2/p53 Early 2 Factor (E2F) Cancer
    MRT00033659 is a potent broad-spectrum kinase inhibitor of CK1 (IC50=0.9 μM for CK1δ) and CHK1 (IC50=0.23 μM). MRT00033659, a pyrazolo-pyridine analogue, induces p53 pathway activation and E2F-1 destabilisation .
    MRT00033659
  • HY-162384
    EPIC-0628

    		Histone Methyltransferase Cancer
    EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .
    EPIC-0628
  • HY-RS17052
    E2f1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    E2f1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for E2f1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    E2f1 Mouse Pre-designed siRNA Set A
    E2f1 Mouse Pre-designed siRNA Set A
  • HY-RS23496
    E2f1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    E2f1 Rat Pre-designed siRNA Set A contains three designed siRNAs for E2f1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    E2f1 Rat Pre-designed siRNA Set A
    E2f1 Rat Pre-designed siRNA Set A
  • HY-RS15353
    UBE2L3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UBE2L3 Human Pre-designed siRNA Set A contains three designed siRNAs for UBE2L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UBE2L3 Human Pre-designed siRNA Set A
    UBE2L3 Human Pre-designed siRNA Set A
  • HY-182902
    IHMT-15137

    		BMX Kinase Apoptosis Cancer
    IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM. IHMT-15137 covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, and disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis. IHMT-15137 reduces E2F1 protein stability via decreased Ser332/337 phosphorylation, increased ubiquitination, and ubiquitin-proteasome pathway degradation. IHMT-15137 induces cell cycle arrest, apoptosis, DNA damage, and suppresses cell migration and invasion. IHMT-15137 can be used for the research of small cell lung cancer .
    IHMT-15137
  • HY-123612
    JAS239

    		Choline Kinase Early 2 Factor (E2F) Fluorescent Dye Neurological Disease Cancer
    JAS239 is a blood-brain barrier-permeable ChoK inhibitor. JAS239 inhibits phosphocholine synthesis and reduces the expression level of E2F1 protein. JAS239 exhibits near-infrared fluorescence properties. JAS239 exerts anti-tumor activity against glioblastoma. JAS239 can be used in studies related to glioblastoma .
    JAS239
  • HY-183118
    CID-078

    		CDK Apoptosis Neurological Disease Cancer
    CID-078 is an orally active macrocyclic cyclin A and cyclin B inhibitor. CID-078 binds cyclin hydrophobic patches, disrupting interactions of cyclin A-Cdk2 with E2F1 and cyclin B-Cdk1 with Myt1, and selectively targets RxL binding motifs to block complex-substrate interactions. CID-078 induces DNA damage, G2/M cell cycle arrest, apoptosis, mitotic catastrophe, spindle assembly checkpoint activation, and neomorphic cyclin B-CDK2 complex formation, driving synthetic lethality in E2F-driven cancer cells. CID-078 can be used for the research of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, advanced solid tumors, luminal HR +/HER 2- breast cancer, RB1-altered solid tumors, and neuroblastoma .
    CID-078

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: